Evidence map›Paper›PMID 37724071›Full record

ArticleMedical review (2021)2021

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives.

Jun Zhou, Zhuoying Ren, Jie Xu, Jifeng Zhang, Y Eugene Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical review (2021), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Cell-cell crosstalk in the heart.Medical review (2021) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun ZhouCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.
Zhuoying RenCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.
Jie XuCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.
Jifeng ZhangCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.
Y Eugene ChenCenter for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.ORCID https://orcid.org/0000-0003-2357-7825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).

Indexed as

cardiovascular diseasesCRISPR/Cas9gene editing therapy

Identifiers

PMID37724071
PMCPMC10471110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.